Enterprise Value
-11.67M
Cash
21.01M
Avg Qtr Burn
-3.268M
Short % of Float
1.13%
Insider Ownership
1.10%
Institutional Own.
12.23%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APVO436 (anti-CD123 x anti-CD3) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 2 Initiation | |
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer | Phase 1 Data readout |